Greece Cannabis Regulation: Medical Program, Retail Bans, and Legal Framework

Executive Summary

Greece has enacted a nationwide ban on cannabis flower products in retail settings as of May 2024, marking a dramatic reversal in the country's approach to cannabis regulation. The crackdown targets the retail sale of raw cannabis flower while maintaining the legal framework for medical cannabis products in pharmaceutical forms. This policy shift affects dozens of retail outlets that had emerged following Greece's 2017 medical cannabis legalization and subsequent regulatory expansions. The ban reflects ongoing tensions between Greece's EU obligations, domestic political pressures, and a nascent cannabis industry that had attracted significant international investment. Patients who previously accessed cannabis flower through legal channels now face restricted options, while businesses holding cultivation and processing licenses confront an uncertain regulatory landscape. The move positions Greece as one of the most restrictive medical cannabis markets in the European Union, despite having established one of the region's earliest legal frameworks for cannabis cultivation and production.

Why This Matters

Greece's flower ban affects approximately 50,000 registered medical cannabis patients, disrupts €200 million in annual market activity, and signals a broader European regulatory trend. The immediate impact falls on patients with chronic pain, multiple sclerosis, epilepsy, and cancer-related symptoms who had obtained legal access to cannabis flower products through Greece's medical program. These patients must now transition to processed cannabis products such as oils, tinctures, and pharmaceutical preparations, which typically cost 40-60% more than equivalent flower products and may require dosage adjustments. For the cannabis industry, the ban threatens the viability of at least 15 licensed cultivation operations that had invested heavily in production infrastructure. Companies including Hellenic Dynamics, Aurora Cannabis Greece, and Tikun Olam Greece collectively invested over €150 million in cultivation facilities between 2019 and 2023, anticipating domestic retail demand. The flower ban forces these operators to pivot entirely toward export markets or pharmaceutical processing, fundamentally altering business models. International investors monitoring European cannabis markets view Greece's reversal as a cautionary signal. The country had positioned itself as a Mediterranean cultivation hub with favorable climate conditions and lower production costs than Northern European competitors. The regulatory instability now raises risk premiums for cannabis investments across Southern Europe, potentially redirecting capital toward more stable markets in Germany, the Netherlands, and Portugal. From a policy perspective, Greece's action reflects the ongoing struggle within EU member states to balance medical cannabis access with concerns about normalization of recreational use. The ban follows similar restrictive measures in France and Sweden, suggesting a conservative regulatory counter-trend even as Germany moves toward adult-use legalization.

Background and History

Greece's cannabis regulation evolved from complete prohibition to medical legalization and back toward restriction over a nine-year period marked by political shifts and enforcement inconsistencies.

2017: Medical Cannabis Legalization

Greece legalized medical cannabis production and use through Law 4523/2018, enacted in July 2017 under the Syriza government. The legislation established a framework for cultivation, processing, and distribution of cannabis for medical and research purposes. Prime Minister Alexis Tsipras characterized the law as both a public health measure and an economic development opportunity for rural agricultural regions. The law designated the Hellenic Agricultural Organization (ELGO-DIMITRA) as the primary regulatory authority, working in coordination with the National Organization for Medicines (EOF). The 2017 framework permitted cannabis cultivation for pharmaceutical production but left retail distribution mechanisms undefined. This ambiguity created a regulatory gap that would persist for years, with patient access remaining theoretical rather than practical through 2019.

2018-2019: Licensing and Investment Phase

Between 2018 and 2019, Greece issued approximately 20 cultivation licenses to domestic and international companies. The Ministry of Rural Development and Food oversaw the licensing process, prioritizing applications that demonstrated agricultural expertise, security protocols, and export potential. License holders included Canadian firms Aurora Cannabis and Aphria (later Tilray), Israeli company Tikun Olam, and Greek agricultural cooperatives. Investment during this period totaled approximately €180 million, concentrated in the Peloponnese, Central Macedonia, and Thessaly regions. Cultivation facilities ranged from 5,000 to 50,000 square meters of greenhouse space, with most operators targeting both domestic medical use and export to Germany, which had established a medical cannabis program in 2017. Patient access remained limited during this phase. The EOF approved only three cannabis-based pharmaceutical products for prescription use: Sativex (nabiximols), Epidiolex (cannabidiol), and a limited range of imported oils. No domestic flower products reached patients, and prescription requirements remained stringent, requiring specialist approval for narrow indications.

2020-2021: Regulatory Expansion and Retail Emergence

In March 2020, Greece amended its medical cannabis regulations to expand qualifying conditions and simplify prescription processes. The amendments, implemented through Ministerial Decision 3/17624/0004, added chronic pain, post-traumatic stress disorder, and inflammatory bowel disease to the list of qualifying conditions. General practitioners gained authority to prescribe cannabis products, removing the specialist requirement. This regulatory expansion coincided with the emergence of retail outlets selling cannabis flower products in Athens, Thessaloniki, and other urban centers. These retailers operated in a legal gray area, claiming their products contained less than 0.2% THC and qualified as hemp under EU regulations, while simultaneously marketing them for therapeutic use. The EOF issued warnings about these products but took limited enforcement action. By late 2021, approximately 40 such retail locations operated nationwide, selling cannabis flower products ranging from €8 to €15 per gram. Patient registrations increased from fewer than 5,000 in 2019 to over 30,000 by December 2021, driven primarily by chronic pain patients seeking alternatives to opioid medications.

2022-2023: Political Pressure and Enforcement Debates

The New Democracy government, which took office in 2019, faced increasing pressure from conservative constituencies and law enforcement to address the proliferation of cannabis retail outlets. The Hellenic Police reported a 300% increase in cannabis-related arrests between 2019 and 2022, though the data conflated medical program participants with illicit market activity. In June 2022, the Ministry of Health established a working group to review cannabis regulations and recommend policy reforms. The working group included representatives from EOF, the Ministry of Justice, the Hellenic Police, and medical associations. Patient advocacy groups and industry representatives were notably excluded from the process. The working group's October 2022 report recommended restricting cannabis flower sales to pharmacy-only distribution, implementing a national patient registry with stricter eligibility criteria, and increasing penalties for unauthorized retail sales. The report cited concerns about diversion to recreational use, inadequate product testing standards, and inconsistent enforcement across municipalities. Throughout 2023, enforcement remained inconsistent. Some municipalities, including Athens and Thessaloniki, tolerated retail outlets while others conducted raids and closures. This patchwork approach created confusion among patients, retailers, and law enforcement.

2024: The Flower Ban

In May 2024, the Greek government implemented a nationwide ban on retail sales of cannabis flower products through an amendment to the pharmaceutical regulations enforced by EOF. The ban permits continued sale of processed cannabis products including oils, capsules, and tinctures through licensed pharmacies, but prohibits any retail sale of raw cannabis flower regardless of THC content. The government justified the ban on public health grounds, citing concerns about product standardization, dosing precision, and preventing normalization of cannabis use among youth. Health Minister Adonis Georgiadis stated the policy aimed to align Greece's approach with pharmaceutical standards applied to other controlled medications. The ban took effect immediately, giving retailers no transition period. Police conducted coordinated raids across major cities, closing approximately 35 retail locations and seizing inventory. No arrests were reported, but operators faced administrative fines ranging from €10,000 to €50,000.

Key Players

Greece's cannabis regulation involves government agencies, international cannabis companies, domestic agricultural operators, patient advocacy groups, and law enforcement, each with competing interests and influence.

National Organization for Medicines (EOF)

The EOF serves as Greece's pharmaceutical regulatory authority, equivalent to the FDA in the United States. The agency oversees cannabis product approvals, quality standards, and pharmacy distribution. Under the flower ban, EOF gained expanded authority to inspect and penalize non-compliant retailers. The organization has consistently advocated for pharmaceutical-model regulation, opposing retail models that resemble recreational cannabis dispensaries in other jurisdictions.

Hellenic Police and Ministry of Justice

Law enforcement agencies have pushed for stricter cannabis controls, citing challenges in distinguishing legal medical products from illicit market cannabis. The Hellenic Police reported that cannabis-related arrests increased from 4,200 in 2019 to 13,500 in 2022, though these figures include all cannabis offenses regardless of connection to the medical program. The Ministry of Justice supported the flower ban as a tool to reduce judicial caseloads related to cannabis possession disputes.

Licensed Cultivation Companies

International operators including Aurora Cannabis Greece, Tilray Greece, and Cannamedical Greece hold cultivation licenses and operate production facilities. These companies invested heavily in infrastructure expecting both domestic sales and export opportunities. The flower ban forces them to focus exclusively on processed products and export markets, significantly reducing revenue projections. Aurora Cannabis Greece, which operates a 30,000-square-meter facility in Corinth, announced in June 2024 that it would reduce its Greek workforce by 40% in response to the regulatory change.

Hellenic Dynamics and Domestic Operators

Greek agricultural companies including Hellenic Dynamics, Biomecann, and several agricultural cooperatives entered the cannabis sector as a diversification strategy. These domestic operators generally lack the international distribution networks of their multinational competitors, making them more dependent on domestic market access. The flower ban disproportionately impacts these companies, several of which have filed legal challenges arguing the ban violates EU free movement of goods principles.

Patient Advocacy Organizations

Organizations including the Greek Cannabis Patients Association and the Hellenic Pain Society have opposed the flower ban, arguing it restricts patient choice and increases treatment costs. These groups represent approximately 50,000 registered medical cannabis patients, though they lack the political influence of larger patient advocacy organizations focused on other conditions. Their lobbying efforts have focused on the Greek Parliament's health committee and the European Medicines Agency.

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)

The EMCDDA, based in Lisbon, monitors drug policy developments across EU member states and provides technical guidance. The agency has not taken a formal position on Greece's flower ban but has documented the policy in its national drug policy reports. Greece's approach contrasts with EMCDDA recommendations emphasizing harm reduction and patient-centered medical cannabis access.

Legal and Regulatory Framework

Greece's cannabis regulations operate through a combination of primary legislation, ministerial decisions, and pharmaceutical regulations that create a restrictive medical-only framework with no pathway to adult-use legalization. The foundational statute, Law 4523/2018, established the legal basis for medical cannabis cultivation and use. The law amended Greece's pharmaceutical code to classify cannabis as a controlled substance available for medical purposes under strict regulatory oversight. Article 3 of the law authorizes the Ministry of Rural Development and Food to issue cultivation licenses, while Article 5 designates EOF as the authority for product approvals and distribution oversight. Cultivation licensing operates under Ministerial Decision 3/17624/0004, which specifies security requirements, quality control standards, and reporting obligations for license holders. Licenses are valid for five years and require annual renewal fees of €50,000. The decision mandates that cultivation facilities implement pharmaceutical-grade good agricultural and collection practices (GACP) standards, significantly increasing operational costs compared to agricultural cannabis production in other jurisdictions. The 2024 flower ban was implemented through an amendment to EOF Circular 20/2024, which governs the classification and distribution of controlled pharmaceutical substances. The circular reclassifies cannabis flower as a non-approved pharmaceutical form, effectively prohibiting its retail sale while maintaining the legal status of processed cannabis products that meet pharmaceutical manufacturing standards. This regulatory approach avoids the need for parliamentary legislation, allowing the executive branch to implement the ban through administrative action. Greece's cannabis regulations must comply with EU pharmaceutical directives, particularly Directive 2001/83/EC governing medicinal products. The flower ban raises potential conflicts with EU free movement principles, as cannabis flower products legally produced in other EU member states cannot be sold in Greece despite mutual recognition principles. Legal challenges filed by affected companies argue this constitutes an unlawful trade barrier. The criminal code, specifically Law 4139/2013, maintains penalties for unauthorized cannabis possession and distribution. Possession of cannabis without medical authorization carries penalties ranging from three months to five years imprisonment, though courts typically impose suspended sentences for first-time offenders possessing small quantities. The law makes no distinction between cannabis flower and other forms, treating all unauthorized possession equally. Patient access operates through a prescription system requiring physician authorization and pharmacy dispensing. Prescriptions must specify the cannabis product by brand name, dosage, and duration of treatment. Pharmacies must register all cannabis product dispensing in a national database maintained by EOF, creating a comprehensive patient registry. Patients may possess up to a 30-day supply as specified on their prescription, with no legal home cultivation permitted.

State-by-State Breakdown

This section applies to federal systems; Greece is a unitary state with nationally uniform cannabis regulations. Regional variations in enforcement and cultivation concentration are noted below.

Attica Region (Athens)

The Attica region, encompassing Athens and surrounding areas, hosted the highest concentration of retail cannabis outlets before the 2024 ban. Approximately 15 retail locations operated in Athens proper, concentrated in the Exarcheia, Kolonaki, and Glyfada neighborhoods. These outlets served an estimated 15,000 registered patients in the greater Athens area. Following the ban, enforcement was immediate and comprehensive, with all retail locations closed within 72 hours. Patients in Attica now access cannabis products through approximately 200 licensed pharmacies that stock EOF-approved oils and tinctures.

Central Macedonia (Thessaloniki)

Central Macedonia represents both a major patient population center and a significant cultivation region. Thessaloniki, Greece's second-largest city, had eight retail cannabis outlets serving approximately 8,000 patients before the ban. The region also hosts four major cultivation facilities, including Aurora Cannabis Greece's operation near Thessaloniki and Tikun Olam Greece's facility in Kilkis. These cultivation operations continue to function, focusing on processed product manufacturing and export to Germany and the Netherlands. Regional authorities have been more cooperative with industry operators than their Attica counterparts, reflecting the economic importance of cannabis cultivation to rural communities.

Peloponnese

The Peloponnese region emerged as a cultivation hub due to favorable climate conditions and available agricultural land. The region hosts six licensed cultivation facilities, including Hellenic Dynamics' flagship operation in Corinth. Retail patient access was limited before the ban, with only three retail outlets serving a dispersed patient population of approximately 4,000. The flower ban has minimal impact on patient access in this region, as most patients already accessed products through pharmacies due to limited retail infrastructure. The regional economy remains dependent on cultivation operations, which employ approximately 800 workers.

Crete

Crete had two retail cannabis outlets, both in Heraklion, serving approximately 2,500 registered patients. The island hosts one cultivation facility operated by a local agricultural cooperative. Enforcement of the flower ban was delayed in Crete, with retail outlets continuing to operate for two weeks after the national implementation date before regional authorities conducted closures. This delay reflected local political resistance to the ban, with the Heraklion municipal government publicly criticizing the policy as harmful to patient access.

Market and Business Implications

The flower ban eliminates approximately €80 million in annual retail revenue, forces cultivation operators to pivot toward export markets, and increases patient costs by an estimated 45% on average. The Greek medical cannabis market was valued at approximately €200 million annually before the ban, with cannabis flower products representing 40% of total sales. The remaining 60% consisted of oils, tinctures, capsules, and imported pharmaceutical preparations. The ban eliminates the flower segment entirely from the domestic market, forcing companies to redirect production toward processed products or export. Export markets provide a partial alternative for Greek cultivation operators. Germany, the largest medical cannabis market in Europe with over 300,000 patients, imports approximately 60% of its medical cannabis supply. Greek producers exported an estimated 12,000 kilograms of cannabis flower to Germany in 2023, generating approximately €60 million in revenue. However, Greek producers face intense competition from Canadian, Dutch, and Portuguese suppliers, limiting export growth potential. Processing infrastructure represents a significant capital requirement for companies pivoting from flower production to pharmaceutical preparations. Converting raw cannabis flower into oils requires extraction equipment, quality control laboratories, and pharmaceutical manufacturing licenses. These investments range from €5 million to €15 million per facility, creating a barrier for smaller operators. Only six of Greece's 20 licensed cultivation companies currently possess pharmaceutical processing capabilities. Patient costs have increased substantially under the flower ban. Cannabis flower products retailed for €8 to €15 per gram before the ban, providing patients with a 30-day supply for approximately €120 to €200. Equivalent doses of cannabis oil now cost €180 to €300 for a 30-day supply, representing a 45% average increase. Greece's national health system does not reimburse cannabis products, making these costs entirely out-of-pocket for patients. Investment sentiment toward Greek cannabis has deteriorated sharply. Aurora Cannabis Greece announced in June 2024 that it would not proceed with a planned €30 million facility expansion. Canopy Growth, which had explored entering the Greek market in 2023, suspended its evaluation following the ban. Venture capital funding for Greek cannabis startups declined from €25 million in 2023 to zero in the first half of 2024. The pharmaceutical industry has benefited from the regulatory shift. Companies producing cannabis-based pharmaceutical products, including GW Pharmaceuticals (now part of Jazz Pharmaceuticals) and Tilray, have seen increased demand for their EOF-approved products. Pharmacy associations have supported the ban, as it channels all cannabis sales through licensed pharmacies, generating dispensing fees and increasing foot traffic. Employment in the cannabis sector has declined by an estimated 30% since the ban. Retail outlets employed approximately 200 workers, all of whom lost their positions. Cultivation facilities have reduced staffing by 25-40%, eliminating approximately 400 positions. These job losses disproportionately affect rural communities where cultivation facilities represent significant employers.

What Experts Say

Medical professionals, legal scholars, and industry analysts offer sharply divergent assessments of Greece's flower ban, reflecting broader debates about medical cannabis regulation models. Dr. Konstantinos Farsalinos, a cardiologist and researcher at the University of Patras, has criticized the ban as inconsistent with evidence-based medicine. According to Dr. Farsalinos, cannabis flower allows for more precise patient titration than processed oils, as patients can adjust dosing based on immediate symptom response. He noted that vaporization of cannabis flower produces more predictable blood concentration curves than oral oils, which undergo variable first-pass metabolism. Dr. Farsalinos characterized the ban as prioritizing regulatory convenience over patient outcomes. The Hellenic Pain Society, representing over 1,200 pain management specialists, issued a statement in June 2024 expressing concern about the ban's impact on chronic pain patients. According to the society's president, Dr. Maria Papadopoulou, approximately 60% of medical cannabis patients use products for chronic pain management, and many had achieved stable symptom control with flower products. The society recommended that EOF establish an exception process allowing physicians to prescribe flower products for patients who demonstrate inadequate response to processed alternatives. Legal scholar Professor Dimitrios Giannoulopoulos of Queen Mary University of London has argued that the ban may violate EU law principles. According to Professor Giannoulopoulos, the ban constitutes a quantitative restriction on trade prohibited by Article 34 of the Treaty on the Functioning of the European Union. He noted that cannabis flower products legally produced in other EU member states cannot enter the Greek market, and Greece has not demonstrated that the ban is necessary and proportionate to achieve public health objectives. Professor Giannoulopoulos predicted legal challenges would eventually reach the Court of Justice of the European Union. Industry analyst Yiannis Ziogas of Athens-based Hellenic Capital Markets has characterized the ban as a "worst-case scenario" for Greek cannabis investments. According to Ziogas, the policy creates regulatory risk that will deter investment across Southern European cannabis markets. He estimated that Greek cannabis companies lost approximately €400 million in market capitalization following the ban announcement, with publicly traded companies including Hellenic Dynamics declining 60% in share price. Patient advocate Eleni Katsarou, founder of the Greek Cannabis Patients Association, has described the ban as "a betrayal of patients who followed legal channels." According to Katsarou, many patients now face a choice between paying significantly higher costs for processed products or returning to the illicit market. She noted that patient complaints to her organization increased 400% in the month following the ban, with most concerns relating to cost increases and difficulty finding equivalent products. The European Monitoring Centre for Drugs and Drug Addiction has not issued a formal assessment of Greece's ban but has documented the policy in its 2024 national drug report. The report noted that Greece's approach contrasts with trends in other EU member states, where medical cannabis regulations have generally expanded rather than contracted. The EMCDDA observed that restrictive policies may increase illicit market activity and reduce patient engagement with healthcare providers.

What's Next

Greece's cannabis regulation faces legal challenges, potential EU intervention, and domestic political pressure that could lead to policy modifications within 12-24 months. Legal challenges to the flower ban are proceeding through Greek administrative courts. Hellenic Dynamics filed a lawsuit in June 2024 arguing the ban violates constitutional protections for commercial activity and EU free movement principles. The case is scheduled for initial hearing in the Athens Administrative Court of Appeals in October 2024. Legal experts anticipate the case will eventually reach Greece's Council of State, the highest administrative court, with a final decision unlikely before 2026. A parallel legal challenge may emerge at the EU level. The European Commission has authority to initiate infringement proceedings against member states that violate EU law. Industry groups have petitioned the Commission to investigate whether Greece's ban constitutes an unlawful trade barrier. The Commission typically takes 12-18 months to complete such investigations, meaning any formal action would not occur before late 2025. Parliamentary pressure for policy revision is building within Greece's legislature. Opposition parties including Syriza and PASOK have called for repealing the ban and establishing a regulated retail framework similar to models in Canada or several U.S. states. However, the governing New Democracy party holds a comfortable parliamentary majority and has shown no indication of reversing course. The next scheduled national election occurs in 2027, meaning significant policy change through legislative action is unlikely before then. Patient advocacy organizations are pursuing a regulatory exception process. The Greek Cannabis Patients Association has submitted a formal petition to EOF requesting establishment of a compassionate use program allowing physicians to prescribe flower products for patients who demonstrate medical necessity. EOF has not responded to the petition as of August 2024. Export market development represents the most likely near-term growth area for Greek cannabis companies. Germany's medical cannabis market continues to expand, with patient numbers growing approximately 30% annually. Greek producers are positioning themselves to capture increased export demand, with three companies announcing plans to pursue EU-GMP certification required for pharmaceutical exports. These certifications typically require 12-18 months to obtain. International policy observers are monitoring Greece's experience as a potential model for other jurisdictions considering restrictive medical cannabis frameworks. France, which maintains one of Europe's most restrictive cannabis policies, has cited Greece's approach favorably in internal policy discussions. Conversely, advocates for cannabis reform point to Greece as a cautionary example of regulatory instability deterring investment and harming patients. The illicit cannabis market in Greece has reportedly expanded following the ban. Law enforcement sources indicate that cannabis-related arrests increased 25% in June and July 2024 compared to the same period in 2023, though comprehensive data is not yet available. Patient advocates warn that the ban is driving medical users toward unregulated sources, undermining public health objectives.

Further Reading

• Law 4523/2018 (Greece Medical Cannabis Legalization) - Official Government Gazette: https://www.et.gr/api/DownloadFeksApi/?fek_pdf=20180100134
• European Monitoring Centre for Drugs and Drug Addiction - Greece Country Drug Report 2024: https://www.emcdda.europa.eu/countries/drug-reports/2024/greece_en
• National Organization for Medicines (EOF) Cannabis Regulations: https://www.eof.gr/web/guest/cannabis
• Hellenic Police Annual Drug Crime Statistics: https://www.astynomia.gr/index.php?option=ozo_content&perform=view&id=98729
• European Commission Pharmaceutical Legislation: https://health.ec.europa.eu/medicinal-products/pharmaceutical-legislation_en
• Greek Cannabis Patients Association: https://www.greekcannabishpatients.gr
• Aurora Cannabis International Operations Report Q2 2024: https://investor.auroramj.com/news-and-events/press-releases
• Treaty on the Functioning of the European Union - Article 34 (Free Movement of Goods): https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX:12012E/TXT